-
More Data on COVID-19 Vaccination and Cancer
Studies indicate that many people with cancer have an antibody response to the vaccines, but this response may be reduced or absent in certain patients.
by Anna Goshua
-
Chemobrain: It’s Not Your Imagination
Scientists discussed the mechanisms of chemotherapy-related cognitive impairment at a session dedicated to symptom science at the AACR Annual Meeting 2021.
by Marci A. Landsmann
-
Immunotherapy Options for Breast Cancer
Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.
by Anna Goshua
-
Cancer and Older Adults: Can Oncologists Do Better?
Geriatric assessment reduces toxicity from treatment and improves quality of life in older adults with cancer.
by Marci A. Landsmann
-
Registries Report on COVID-19 and Cancer
Data shed light on risk factors for death among people with cancer infected with the coronavirus.
by Kate Yandell
-
Using Leftover Cancer Drugs to Help Others
Cancer drug repositories that accept unused drugs could provide an affordable source of medications for patients in need, while also providing patients left with extra drugs a way to give back.
by Jon Kelvey
-
Facing Cancer and a Pandemic at the Same Time
Cancer patients and their families share stories of fear, love and uncertainty as they find new ways to support each other.
by Jen Tota McGivney
-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast Cancer
Studies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
-
A Switch From Intravenous to Oral Chemo?
Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
-
Learning the Language of Chemotherapy
Cancer patients often do not understand words their doctors use while talking about chemotherapy, but a new video series helps explain these terms.
by Jen Tota McGivney
Cancer Talk
Delaying Treatment Resistance
Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
2024: The Year in Cancer NewsThe Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff
Cancer Today Editors’ Picks: 2024Our favorite Cancer Today stories from 2024, as picked by the editors.
Rethinking the Role of RadiationChest radiation may not be necessary for people with intermediate-risk breast cancer.
by Thomas Celona